Eli Lilly (LLY) Shares Outstanding (Diluted Average) (2016 - 2026)
Eli Lilly filings provide 15 years of Shares Outstanding (Diluted Average) readings, the most recent being $895.9 million for Q1 2026.
- On a quarterly basis, Shares Outstanding (Diluted Average) fell 0.52% to $895.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $895.9 million, a 0.52% decrease, with the full-year FY2025 number at $899.3 million, down 0.53% from a year prior.
- Shares Outstanding (Diluted Average) hit $895.9 million in Q1 2026 for Eli Lilly, roughly flat from $899.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $906.4 million in Q1 2022 to a low of $895.9 million in Q1 2026.
- Median Shares Outstanding (Diluted Average) over the past 5 years was $903.3 million (2023), compared with a mean of $902.6 million.
- Biggest five-year swings in Shares Outstanding (Diluted Average): decreased 0.79% in 2022 and later increased 0.14% in 2024.
- Eli Lilly's Shares Outstanding (Diluted Average) stood at $904.6 million in 2022, then fell by 0.15% to $903.3 million in 2023, then increased by 0.09% to $904.1 million in 2024, then decreased by 0.53% to $899.3 million in 2025, then decreased by 0.38% to $895.9 million in 2026.
- The last three reported values for Shares Outstanding (Diluted Average) were $895.9 million (Q1 2026), $899.3 million (Q4 2025), and $898.8 million (Q3 2025) per Business Quant data.